Allergy Therapeutics Company Profile

14:45 EDT 22nd June 2018 | BioPortfolio

Allergy Therapeutics®. (AT) is a Europe-based specialty pharmaceutical company focused upon the treatment and prevention of allergy. AT has an existing sales base of approximately £19m/€27m per annum, an MHRA-approved manufacturing capability and an established sales and marketing infrastructure in several major European markets. In addition, the Company has a number of novel compounds which have already undergone initial clinical evaluation and once registered could potentially revolutionise the treatment of allergy. An established range of specific immunotherapy diagnostics and therapies, generating growing revenues of approximately £19m/€27m per annum.
Certain exclusive rights to MPL®, a novel immunological adjuvant in the field of allergy, licensed from Corixa Corporation.
An innovative product development pipeline supported by documented clinical evidence of efficacy and safety.
Intellectual property rights to five patent families with further rights to the use of MPL® in new formulations. Patent protection for new products extends to the years 2018-20.
A highly qualified scientific and commercial team with industry experienced management.
A European sales and marketing team in Germany, Italy and Spain.
High quality facilities, including cGMP manufacturing, capable of increased production capacity.


Dominion Way
West Sussex
BN14 8SA
United Kingdom


Phone: 44 1903 844700
Fax: 44 1903 844744

News Articles [1218 Associated News Articles listed on BioPortfolio]

Allergy Therapeutics' latest data highlights benefits of adjuvant technology

Commercial biotechnology firm Allergy Therapeutics on Monday published new data highlighting its technology's effectiveness as an adjuvant compared to existing treatments. According to Allergy Ther...

DGAP-News: Allergy Therapeutics plc veröffentlicht Update zur Geschäftsentwicklung (deutsch)

Allergy Therapeutics plc veröffentlicht Update zur Geschäftsentwicklung DGAP-News: Allergy Therapeutics plc / Schlagwort(e): Umsatzentwicklung Allergy Therapeutics plc veröffentlicht Update zur Ge....

Grass Pollen Allergy Vaccine Gets Encouraging Phase II Results

Allergy Therapeutics has obtained positive Phase II results for its grass pollen allergy vaccine and plans to launch a Phase III study next year. British biotech Allergy Therapeutics has obtained posi...

Allergy Therapeutics readies grass pollen treatment for phase III trial after “extremely positive” mid-stage results

The phase II study of Allergy Therapeutics’ PQ Grass immunotherapy – an aluminium-free, ultra-short course hay fever treatment – evaluated dose response and safety

Allergy Therapeutics highlights benefits of adjuvant technology in new paper

The study highlighted Allergy’s microcrystalline tyrosine (MCT) was a suitable and flexible alternative to aluminium hydroxide

Intrommune Therapeutics Submits Pre-IND Meeting Request to the U.S. FDA for INT301, Its Peanut Allergy Oral Mucosal Immunotherapy Drug Candidate, During Food Allergy Awareness Week

New York, May 15, 2018 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a NYC-based biopharmaceutical company developing a patient-friendly immunotherapy platform for the treatment of food all...

'Pivotal' year ahead for Allergy Therapeutics with key trial readouts

Nick Wykeman and Manuel Llobet from Allergy Therapeutics plc (LON:AGY) caught up with Proactive Investors following the release of their interim results. Allergy's continued to gain market share a...

Ergomed Plc adds to co-development pipeline with Allergy Therapeutics deal

Andrew Mackie, chief business officer at Ergomed Plc (LON:ERGO), caught up with Proactive to discuss their co-development agreement with Allergy Therapeutics plc (LON:AGY). Under the terms of the ...

PubMed Articles [1222 Associated PubMed Articles listed on BioPortfolio]

A Retrospective Critical Analysis and Risk Stratification of Penicillin Allergy De-labelling in a UK Specialist Regional Allergy Service.

A spurious label of penicillin allergy (Pen-A) negatively impacts on antibiotic stewardship and healthcare costs. Recent studies have proposed a guideline-steered direct penicillin challenge without u...

Anaphylaxis by exclusive allergy to swordfish and identification of a new fish allergen.

Fish allergy affects up to 7% of the worldwide population, with variations between countries mostly stemming from consumption rates and methods of allergy diagnosis. In Spain, where fish consumption i...

Predictors of Persistent Wheat Allergy in Children: A Retrospective Cohort Study.

Wheat allergy is the third most common food allergy that develops during infancy in Japan. To identify factors associated with persistent wheat allergy, we assessed the rate of tolerance acquisition a...

Efficacy and safety of five-day challenge for the evaluation of non-severe amoxicillin allergy in children.

Penicillin allergy is the most frequent drug allergy, among which aminopenicillins are reputed for causing delayed rashes in children, particularly in the context of viral infections. Despite a negati...

The Genetics of Food Allergy.

Food allergy likely arises from a complex interplay between environmental triggers and genetic susceptibility. Here, we review recent studies that have investigated the genetic pathways and mechanisms...

Clinical Trials [594 Associated Clinical Trials listed on BioPortfolio]

The Influence of Early and Continuous Exposure of Infants to Cow's Milk Formula on the Prevention of Milk Allergy

Cow's milk protein (CMP) allergy is one of the most common food allergies and potentially a fatal one. Early feeding with CMP has been considered in the past as a risk factor for developme...

Anti-TSLP (AMG 157) Plus Antigen-Specific Immunotherapy for Induction of Tolerance in Individuals With Cat Allergy

The purpose of this research study is to find out if cat allergy shots with combination with AMG 157, an experimental medication, will help the cat allergy shots work after just one year o...

Effectiveness of Cat-PAD to Treat Cat Allergy in Cat Allergic Subjects

Cat allergy is an increasingly prevalent condition, affecting 10-15% of patients with allergic rhinoconjunctivitis and/or asthma. Cat-PAD is a novel, synthetic, allergen-derived peptide d...

Sublingual Milk Immunotherapy in Children

Sublingual immunotherapy is developing in the treatment of aeroallergens allergy. The hypothesis is that such process may be applied to food allergy, more precisely to milk. A previous se...

The Effect of Per Oral Immunotherapy in Severe Milk, Peanut and Egg Allergy in Adults

The aim is to analyse the results of per oral immunotherapy treatment in severe milk, peanut or egg allergy in adults. This is the second part of the oral immunotherapy study in adults at ...

Companies [1387 Associated Companies listed on BioPortfolio]

Allergy Cure

Allergies like food allergies i.e. Peanut allergy wheat allergy milk allergy dog allergies cat allergies latex allergy skin allergies dust mites allergy cure by Aller-X herbal Medicine admark herba...

Prota Therapeutics Pty Ltd

Prota Therapeutics is a newly established Australian private company developing immunotherapy based treatments for food allergy. The company’s lead product based on innovativ...

HAL Allergy Group

The HAL Allergy Group ( was established in 1959 and is a main European manufacturer of allergy vaccines and diagnostics. The Group's products are distributed via subsidi...

Planet Technologies

On March 9, 2005, Planet announced a definitive agreement to acquire privately-owned Allergy Control Products. The combination of Planet’s Allergy Free business with Allergy Control will create one ...

Allergy Therapeutics

Allergy Therapeutics®. (AT) is a Europe-based specialty pharmaceutical company focused upon the treatment and prevention of allergy. AT has an existing sales base of approximately £19m/€27m per an...

More Information about "Allergy Therapeutics" on BioPortfolio

We have published hundreds of Allergy Therapeutics news stories on BioPortfolio along with dozens of Allergy Therapeutics Clinical Trials and PubMed Articles about Allergy Therapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Allergy Therapeutics Companies in our database. You can also find out about relevant Allergy Therapeutics Drugs and Medications on this site too.

Quick Search


Relevant Topics

The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Corporate Database Quicklinks

Searches Linking to this Company Record